Featured Articles
SPECIAL FEATURE - Injection Devices: Advancements Converge to Expand Patient Possibilities
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
ARTIFICIAL INTELLIGENCE - AI/ML Supporting Biomarker & Target Discovery
William Whitford explains how Artificial Intelligence/Machine Learning provide new capabilities in analyzing the rapidly increasing type and amount of biological data employed in identifying potential biomarker and disease targets.
EXECUTIVE INTERVIEW - Portal Instruments: Beyond Springs – Portal Prime Nexus™ Autoinjector is a Versatile Solution for Biologics
As biologics become larger, more viscous, and more complex, software offers a fundamentally better way to control and optimize delivery.
PLATFORM TECHNOLOGY - How a Novel Immunotherapy Platform is Unlocking the Cancer-Fighting Potential of Unconventional T Cells
Michal Sheleg, PhD, shines a spotlight on the promise of MAIT cells to fight cancer by turning to an untapped source: human placentas.
FORMULATION FORUM - High Concentration Biologics for Injectable Drug Delivery
Shaukat Ali, PhD, and Jim Huang, PhD, discuss how the development of high- and ultra-high-concentration biologics aims to enable smaller-volume, patient-friendly subcutaneous injections.
DELIVERY SYSTEM DEVELOPMENT - Supporting Earlier Delivery-System Decisions in Injectable Drug Development Through a USP <382>-Aligned System-Level Approach
Sarah Masucci and Crystal Salvans highlight a shift from evaluating individual syringe components independently toward system-level qualification of the complete PFS container-closure system, with the goal of simplifying development and supporting product quality and regulatory expectations.
LYOPHILIZATION - Great Expectations: Selecting & Managing CDMO Partnerships for Lyophilized Injectables from Development Through Commercialization
Carrie A. Schults outlines considerations of managing these partnerships with an emphasis on proactive risk management to control timelines and cost.
QUALITY MANAGEMENT SYSTEM - One QMS, Four Delivery Platforms: Can Your Quality System Manage Complexity at Scale?
Melanie Cerullo emphasizes that when quality systems manage rather than react to complexity, faster development and safer more effective medicines ensue.
REGULATORY COMPLIANCE - Navigating ISO 23908:2024 & EN ISO 23908:2025 Harmonization: What It Means for Your Combination Product Strategy
Murtaza Rana and Aurélie Rebuffet reflect on how a revised standard is an opportunity to reassess how sharps injury risks are addressed across product development, regulatory submissions, and lifecycle management
25 Years of Trust, Partnership & Progress
To Our Readers, Advertising Partners, and Industry Colleagues, When Drug Development & Delivery began in 2001, the pharmaceutical and life sciences landscape looked very different…
2026 Sustainable Drug Development & Delivery eBook: Pharma Needs A Risk-Based Strategy Toward Sustainability
As sustainability expectations continue to rise across the pharmaceutical industry, drug makers, CDMOs, and equipment suppliers are under increasing pressure to reduce waste, energy use, and environmental impact. Find out in this exclusive Drug Development & Delivery eBook how companies like Bespak have taken steps to support the scale of commercial-scale manufacturing of a low-carbon Pressurized Metered Dose Inhaler. Additionally, learn how Aptar Pharma Injectables division has undertaken an effort to identify the principal sources of emissions across its elastomeric closure solutions. Finally, a new sustainability report reveals what the pharma industry is doing particularly well – and not so well – in its sustainability endeavors.
2026 Nasal & Inhalation Drug Development & Delivery eBook: Drug Repurposing Creates New Market Opportunities
In this exclusive seventh annual nasal and inhalation eBook, Drug Development & Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases. We also explore the challenges of nose-to-brain delivery, next-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Connecting Your Project to the Right Service Provider
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
SPECIAL REPORT - Advancements in Respiratory Drug Delivery
Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.
EXECUTIVE INTERVIEW - Dr. Michalis Papadakis Founder & CEO Brainomix
Brainomix founder and CEO Dr. Michalis Papadakis discusses how AI-powered imaging is helping drug developers improve clinical trial design, identify meaningful treatment effects, and advance new therapies in stroke, pulmonary fibrosis, and other areas of unmet need.
CAR T CELL THERAPY - The Rise of Scalable Allogeneic CAR T: Shaping a New Era in Oncology
Allogeneic CAR T therapies are helping move oncology toward more scalable, off-the-shelf treatment models that could expand access, support earlier intervention, and bring advanced cell therapy closer to community cancer settings.
DRUG DELIVERY - Improved Prediction of Food Effect on Oral Absorption
Dissolution-permeation testing is helping drug developers better predict how food affects oral drug absorption by measuring both drug solubilization and membrane permeation, reducing the risk of misleading results from dissolution data alone.
DRUG-DEVICE COMBINATION PRODUCTS - Incorporating Self-Administered Drug-Device Combination Products Into Clinical Trials Can Bring Outsized Challenges & Outstanding Rewards
Self-administered drug-device combination products can bring major benefits to clinical trials, improving patient convenience, dosing consistency, compliance, and real-world insight, but they require careful early planning around usability, safety, regulatory requirements, compatibility, manufacturing, and scale-up.
DRUG DEVELOPMENT - Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development
Drug combination screening is helping oncology developers identify synergistic drug pairs, connect response patterns to tumor biology, and support more predictive, biomarker-guided strategies for precision cancer treatment.
SINGLE B CELL ANTIBODY DISCOVERY - Improving Therapeutic Candidate Selection in Drug Development
Single B cell antibody discovery is helping improve therapeutic candidate selection by preserving native heavy- and light-chain pairing, accelerating sequence-defined screening, and enabling earlier identification of candidates with stronger specificity, function, and developability.
